NEXGEL, Inc.

NasdaqCM NXGL

NEXGEL, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2024: -76.97%

NEXGEL, Inc. Return on Equity (ROE) is -76.97% for the Trailing 12 Months (TTM) ending September 30, 2024, a -97.09% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

NEXGEL, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -39.05%, a 46.33% change year over year.
NEXGEL, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -72.76%, a 90.10% change year over year.
NEXGEL, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -735.31%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqCM: NXGL

NEXGEL, Inc.

CEO	Mr. Adam R. Levy
IPO Date	Dec. 22, 2021
Location	United States
Headquarters	2150 Cabot Boulevard West
Employees	19
Sector	Materials
Industries Plastics 3D Printing Biotechnology Chemicals & Advanced Materials Cleaning Supplies Composite Materials Medical Instruments Personal Care

Description

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.

Key trends

Past 5 years